Andrew Wilfin

Statistics

Publications

Citations

H-Index

Active since

2025

Affiliations

Vertex Pharmaceuticals (United States)(Current)

Andrew Wilfin is an author at Vertex Pharmaceuticals (United States) specializing in ivacaftor therapy, cohort study investigation, and internal medicine.

Publications per year

2025–2025

Publications

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

G. Vega-Hernández, Gordon MacGregor, Andrew Wilfin et al. · Journal of Cystic Fibrosis · 2025 · 11 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

1–1 of 1